vs
CSG SYSTEMS INTERNATIONAL INC（CSGS）とOrthofix Medical Inc.（OFIX）の財務データ比較。上の社名をクリックして会社を切り替えられます
CSG SYSTEMS INTERNATIONAL INCの直近四半期売上が大きい（$323.1M vs $219.9M、Orthofix Medical Inc.の約1.5倍）。CSG SYSTEMS INTERNATIONAL INCの純利益率が高く（2.2% vs -1.0%、差は3.2%）。CSG SYSTEMS INTERNATIONAL INCの前年同期比売上増加率が高い（2.0% vs 2.0%）。CSG SYSTEMS INTERNATIONAL INCの直近四半期フリーキャッシュフローが多い（$55.8M vs $16.8M）。過去8四半期でOrthofix Medical Inc.の売上複合成長率が高い（8.0% vs 4.6%）
中国南玻集団股フン有限公司は中国最大級の建築用ガラスメーカーで、浮きガラス、建築用ガラス、ディスプレイ用ガラス、自動車用ガラス、コーティングガラス、鏡、カラーフィルターガラス、太陽光発電用ガラス、省エネガラスなど多種多様なガラス製品の製造・販売を手がけています。
オーソフィックスメディカル社は世界的な整形外科医療機器メーカーで、脊椎インプラント、整形外科用外傷治療製品、骨成長刺激療法機器、再生医療製品の開発・製造・販売を事業としています。北米、欧州、アジア太平洋を中心に整形外科医や医療機関向けに製品を提供し、筋骨格系疾患患者の治療成績向上に取り組んでいます。
CSGS vs OFIX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $323.1M | $219.9M |
| 純利益 | $7.0M | $-2.2M |
| 粗利率 | 50.0% | 71.1% |
| 営業利益率 | 9.0% | 0.2% |
| 純利益率 | 2.2% | -1.0% |
| 売上前年比 | 2.0% | 2.0% |
| 純利益前年比 | -79.7% | 92.4% |
| EPS（希薄化後） | $0.24 | $-0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $323.1M | $219.9M | ||
| Q3 25 | $303.6M | $205.6M | ||
| Q2 25 | $297.1M | $203.1M | ||
| Q1 25 | $299.5M | $193.6M | ||
| Q4 24 | $316.7M | $215.7M | ||
| Q3 24 | $295.1M | $196.6M | ||
| Q2 24 | $290.3M | $198.6M | ||
| Q1 24 | $295.1M | $188.6M |
| Q4 25 | $7.0M | $-2.2M | ||
| Q3 25 | $20.5M | $-22.8M | ||
| Q2 25 | $12.3M | $-14.1M | ||
| Q1 25 | $16.1M | $-53.1M | ||
| Q4 24 | $34.5M | $-29.1M | ||
| Q3 24 | $19.1M | $-27.4M | ||
| Q2 24 | $13.8M | $-33.4M | ||
| Q1 24 | $19.5M | $-36.0M |
| Q4 25 | 50.0% | 71.1% | ||
| Q3 25 | 48.1% | 72.2% | ||
| Q2 25 | 49.5% | 68.7% | ||
| Q1 25 | 48.4% | 62.8% | ||
| Q4 24 | 51.3% | 69.0% | ||
| Q3 24 | 49.4% | 68.7% | ||
| Q2 24 | 47.3% | 67.8% | ||
| Q1 24 | 46.5% | 67.5% |
| Q4 25 | 9.0% | 0.2% | ||
| Q3 25 | 10.0% | -8.3% | ||
| Q2 25 | 10.0% | -7.9% | ||
| Q1 25 | 9.8% | -25.2% | ||
| Q4 24 | 13.4% | -5.3% | ||
| Q3 24 | 10.8% | -9.6% | ||
| Q2 24 | 8.8% | -12.5% | ||
| Q1 24 | 10.8% | -15.6% |
| Q4 25 | 2.2% | -1.0% | ||
| Q3 25 | 6.7% | -11.1% | ||
| Q2 25 | 4.1% | -6.9% | ||
| Q1 25 | 5.4% | -27.4% | ||
| Q4 24 | 10.9% | -13.5% | ||
| Q3 24 | 6.5% | -13.9% | ||
| Q2 24 | 4.8% | -16.8% | ||
| Q1 24 | 6.6% | -19.1% |
| Q4 25 | $0.24 | $-0.05 | ||
| Q3 25 | $0.73 | $-0.57 | ||
| Q2 25 | $0.44 | $-0.36 | ||
| Q1 25 | $0.57 | $-1.35 | ||
| Q4 24 | $1.20 | $-0.76 | ||
| Q3 24 | $0.67 | $-0.71 | ||
| Q2 24 | $0.48 | $-0.88 | ||
| Q1 24 | $0.68 | $-0.95 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.0M | $82.0M |
| 総負債低いほど良い | $539.5M | — |
| 株主資本純資産 | $283.7M | $450.0M |
| 総資産 | $1.5B | $850.6M |
| 負債/資本比率低いほどレバレッジが低い | 1.90× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $180.0M | $82.0M | ||
| Q3 25 | $158.4M | $62.9M | ||
| Q2 25 | $145.9M | $65.6M | ||
| Q1 25 | $136.0M | $58.0M | ||
| Q4 24 | $161.8M | $83.2M | ||
| Q3 24 | $118.4M | $30.1M | ||
| Q2 24 | $110.4M | $26.4M | ||
| Q1 24 | $120.8M | $27.0M |
| Q4 25 | $539.5M | — | ||
| Q3 25 | $538.6M | $157.2M | ||
| Q2 25 | $537.8M | $157.0M | ||
| Q1 25 | $537.6M | $156.9M | ||
| Q4 24 | $538.5M | $157.0M | ||
| Q3 24 | $539.5M | $118.5M | ||
| Q2 24 | $540.5M | $118.0M | ||
| Q1 24 | $541.5M | $118.2M |
| Q4 25 | $283.7M | $450.0M | ||
| Q3 25 | $289.5M | $442.5M | ||
| Q2 25 | $290.7M | $458.3M | ||
| Q1 25 | $283.1M | $458.3M | ||
| Q4 24 | $282.6M | $503.1M | ||
| Q3 24 | $288.4M | $525.9M | ||
| Q2 24 | $273.3M | $546.0M | ||
| Q1 24 | $269.3M | $570.3M |
| Q4 25 | $1.5B | $850.6M | ||
| Q3 25 | $1.5B | $832.6M | ||
| Q2 25 | $1.4B | $837.2M | ||
| Q1 25 | $1.4B | $823.1M | ||
| Q4 24 | $1.5B | $893.3M | ||
| Q3 24 | $1.4B | $867.9M | ||
| Q2 24 | $1.4B | $882.0M | ||
| Q1 24 | $1.3B | $906.0M |
| Q4 25 | 1.90× | — | ||
| Q3 25 | 1.86× | 0.36× | ||
| Q2 25 | 1.85× | 0.34× | ||
| Q1 25 | 1.90× | 0.34× | ||
| Q4 24 | 1.91× | 0.31× | ||
| Q3 24 | 1.87× | 0.23× | ||
| Q2 24 | 1.98× | 0.22× | ||
| Q1 24 | 2.01× | 0.21× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $59.2M | $27.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $55.8M | $16.8M |
| FCFマージンFCF / 売上 | 17.3% | 7.6% |
| 設備投資強度設備投資 / 売上 | 1.1% | 4.9% |
| キャッシュ転換率営業CF / 純利益 | 8.46× | — |
| 直近12ヶ月FCF直近4四半期 | $141.4M | $-1.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $59.2M | $27.7M | ||
| Q3 25 | $47.9M | $12.4M | ||
| Q2 25 | $37.3M | $11.6M | ||
| Q1 25 | $11.5M | $-18.4M | ||
| Q4 24 | $82.5M | $23.7M | ||
| Q3 24 | $39.5M | $11.7M | ||
| Q2 24 | $43.1M | $9.0M | ||
| Q1 24 | $-29.4M | $-18.6M |
| Q4 25 | $55.8M | $16.8M | ||
| Q3 25 | $43.9M | $2.5M | ||
| Q2 25 | $34.6M | $4.5M | ||
| Q1 25 | $7.1M | $-25.1M | ||
| Q4 24 | $76.6M | $15.2M | ||
| Q3 24 | $32.0M | $6.3M | ||
| Q2 24 | $38.8M | $-360.0K | ||
| Q1 24 | $-34.1M | $-29.1M |
| Q4 25 | 17.3% | 7.6% | ||
| Q3 25 | 14.5% | 1.2% | ||
| Q2 25 | 11.6% | 2.2% | ||
| Q1 25 | 2.4% | -13.0% | ||
| Q4 24 | 24.2% | 7.0% | ||
| Q3 24 | 10.8% | 3.2% | ||
| Q2 24 | 13.4% | -0.2% | ||
| Q1 24 | -11.6% | -15.4% |
| Q4 25 | 1.1% | 4.9% | ||
| Q3 25 | 1.3% | 4.8% | ||
| Q2 25 | 0.9% | 3.5% | ||
| Q1 25 | 1.5% | 3.5% | ||
| Q4 24 | 1.9% | 4.0% | ||
| Q3 24 | 2.5% | 2.7% | ||
| Q2 24 | 1.5% | 4.7% | ||
| Q1 24 | 1.6% | 5.6% |
| Q4 25 | 8.46× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 3.04× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 2.39× | — | ||
| Q3 24 | 2.07× | — | ||
| Q2 24 | 3.12× | — | ||
| Q1 24 | -1.51× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
